1.

Selenium-containing water-soluble polymers and their conjugates

Patent application relates to SelenoPEG reagents for sitespecific PEGylation to cysteines. Stabilizing effect is achieved because bond is cleavable in the presence of small amounts of reducing agents enabling release of fully active protein in blood, environment with significant amount of reducing agent.

F.32 International patent

COBISS.SI-ID: 1518684

2.

Antibacterial combination of a tricyclic carbapenem and an antibiotic

Patent application relates to pharmaceutical composition comprising an ethylene derivatives of tricyclic carbapenems in a form of pure diastereoisomers and in the form of pure geometric isomers or a salt, ester or amide derivate thereof and an antibiotic and the use of this composition as a broad band spectrum betalactamase inhibitor.

F.32 International patent

COBISS.SI-ID: 4059418

3.

Process for the production of increased amounts of correctly folded heterologous protein in inclusion bodies

Granted international patent covering preparation of recombinant proteins in E.coli in the form of nonclassical inclusion bodies with high amount of correctly folded protein.

F.32 International patent

COBISS.SI-ID: 3015194

4.

Support to facility construction and establishing of manufacturing for modified proteins in Lek, Mengeš, development of PEGylated biopharmaceuticals and process transfer to production

Members of the program group have been performed development of technological processes for two PEGylated biopharmaceuticals, biosimilar and the innovative biologics. We have successfully transferred both processes to the large scale manufacturing and support clinical GMP manufacturing. Additionally, we supported the design and construction of a plant for the production of modified (PEGylated) proteins in Mengeš. Start of regular manufacturing is expected after 2015. A program group member S. Jevševar played a key role in all phases, not only in terms of expertise, but she also managed development work in the laboratory phase. Her role and scientific contribution, which was transferred into practice as well, was recognized in 2010 by Novartis' global award VIVA (Vision, Innovation, Values & Achievement, which is granted to Novartis leading scientists.

F.17 Transfer of existing technologies, know-how, methods and procedures into practice

5.

Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy-acetyl)-L-alanyl-D-glutamic acid (LK-423)

The present invention relates to the pharmaceutical dosage forms which enabled a controlled and/or a targeted drug delivery of an active substance tothe selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2phthalimidoethoxy-acetyl)-L-alanyl-D-glutamic acid (designed as LK-423).Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.

F.32 International patent

COBISS.SI-ID: 1812337